FDA to examine CV side effects of several meds

Published on Wednesday 19 November 2008 - 15:02

Summary :
Dr. John Jenkins, the director of the FDA's Office of New Drugs, says that one of the agency's top concerns are the cardiovascular risks associated with many drugs aimed at treating chronic...
Read more

Information source

http://www.fiercepharma.com/news/frontpage

Website description
Find pharmaceutical news on the pharma industry, pharma companies, FDA regulations and much more. Sign up today for a free daily pharma briefing.

Articles published on this website : 0 / 7 days - 4 / 30 days

AZ's Brennan sees "top-line" challenges ahead Schering-Plough stock down on Vytorin sales EU officials seize 34M counterfeit medicines Abbott's TriCor follow-up gets FDA nod Cigna cuts patients' costs for Lipitor

Other articles published on other websites on the same day

GOING NUTTY http://www.todayonline.com/ ORIGINAL ARTICLE: Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein http://content.nejm.org/ Healthwatch for Nov. 19, 2008 http://www.statejournal.com/ Statins For All? Not So Fast, Expert Says http://www.wxii12.com/ A Heavy Heart: The FDA Weighs CV Side Effects http://www.pharmalot.com/ Convergence08 http://nextbigfuture.com/ Mind Reader http://www.portfolio.com/ Drugs may Delay artery Damage in Children http://tomsrivertimes.micromediapubs.com/ New possibilites for next fall screenings at Loan Closet http://www.hsvvoice.com/ Nine Spanish Wineries Present an R&D Project to Increase the Beneficial Effects of Wine on Health http://www.newswiretoday.com/